Cure8 news brief
If you have moderate to severe Crohn’s disease, this study suggests some patients who don’t respond to initial risankizumab induction may still benefit from a longer induction period, including improved symptoms and endoscopic measures.
That could affect expectations about how quickly a drug works and decisions about continuing therapy past an initial induction window.
Adults with moderate to severe Crohn’s disease, patients and caregivers considering or receiving risankizumab (Skyrizi), gastroenterologists and IBD clinicians, and researchers studying biologic induction and maintenance strategies.
This Healio article reports on an analysis of phase 3 induction and an extended-induction study of risankizumab (Skyrizi) in moderate to severe Crohn’s disease.
It summarizes that many patients who did not respond to the initial IV induction achieved clinical and endoscopic responses after an additional 12 weeks of treatment, and that delayed responders could continue into maintenance therapy.
The piece notes dosing arms used in the extension (IV 1,200 mg and subcutaneous 180 mg or 360 mg) and that no new safety signals were identified; it also cites the reported study limitations and funding by AbbVie.
Details and context The article focuses on efficacy endpoints such as stool frequency/abdominal pain (SF/APS), CDAI, and endoscopic response/remission at week 24 and continued outcomes to week 52 for maintenance dosing.
It highlights that extended treatment produced higher overall response rates and that the 360 mg subcutaneous group had higher efficacy versus 180 mg in some analyses. Tone and limitations This is a news summary of a published clinical study (Clin Gastroenterol Hepatol) and includes investigator comments and disclosures.
It does not provide individual patient guidance or new prescribing recommendations.
This summarizes phase 3 trial data and an extended-induction analysis; the study was funded by AbbVie and includes investigator disclosures. Extended induction effects and dosing differences are reported in the trial publication; this news item does not change clinical recommendations on its own.
Consult the original Clin Gastroenterol Hepatol paper for full methods, limitations, and statistical details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the...
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
